Nanobiotix SA is a leading company that represents several core values and a strong corporate philosophy. With a focus on innovation and cutting-edge technology, Nanobiotix is dedicated to revolutionizing cancer treatment with its proprietary nanomedicine platform. The company believes in the power of collaboration, working closely with research institutions, healthcare professionals, and patients to develop groundbreaking therapies. Nanobiotix is committed to excellence, ensuring the highest quality in its products and services. Moreover, the company is guided by a sense of responsibility towards patients and society, striving to make a positive impact in the field of oncology. Nanobiotix SA embodies a vision of advancing cancer care through innovative, patient-centric solutions.

Nanobiotix SA is primarily present in various countries and regions globally. The company has established its presence in Europe, including France, Germany, Spain, and the United Kingdom. Additionally, Nanobiotix SA has expanded its operations and collaborations in the United States, where it aims to advance its innovative solutions. With a rapidly growing international reach, Nanobiotix SA is continuously striving to strengthen its presence in key markets and establish valuable partnerships to further enhance its position in the field of biotechnology and nanomedicine.

Nanobiotix SA, a leading biotechnology company, has achieved several significant milestones. The company's innovative approach to cancer treatment has garnered attention and accolades. Nanobiotix SA successfully completed the Phase III study of its flagship product, NBTXR3, demonstrating its efficacy in improving outcomes for patients with locally advanced soft tissue sarcoma. Additionally, Nanobiotix SA has secured various collaborations and partnerships with renowned organizations, highlighting their commitment to advancing research and development. By consistently pushing boundaries and pioneering new therapeutic solutions, Nanobiotix SA continues to make impressive strides in the field of oncology and remains a prominent player in the industry.

Nanobiotix SA is a French nanomedicine company specializing in the development of innovative cancer therapies. Established in 2003, the company has made significant advancements in the field of nanomedicine, particularly in the area of radiotherapy. Nanobiotix SA's flagship product, NBTXR3, is a first-in-class nanoparticle designed to enhance the efficacy of radiotherapy in various solid tumors. With a strong focus on research and development, Nanobiotix SA has received regulatory approvals in multiple countries and has established strategic collaborations with renowned organizations. As a pioneering player in nanomedicine, Nanobiotix SA is committed to revolutionizing cancer treatment and improving the lives of patients worldwide.

The main competitors of Nanobiotix SA in the market include companies such as CytRx Corporation, DelSiTech Ltd., OncoSec Medical Incorporated, and Sol-Gel Technologies Ltd. These companies operate in the field of oncology and drug delivery technologies, just like Nanobiotix SA. However, Nanobiotix SA differentiates itself through its innovative technology called the NanoXray platform, which enables localized tumor treatment. With its unique approach and strong pipeline, Nanobiotix SA aims to establish a leading position in the global oncology market.

Nanobiotix SA primarily operates in the healthcare and biotechnology industries.

The business model of Nanobiotix SA is focused on developing and commercializing innovative nanoparticle-based therapeutic products for cancer treatment. The company utilizes its proprietary nanotechnology platform, NanoXray, to enhance the efficacy of radiotherapy by targeting tumors. Nanobiotix SA aims to revolutionize cancer treatment by providing personalized and effective therapies through the development of its lead product, NBTXR3. This product has the potential to be used across various cancer indications and has shown promising results in clinical trials. Nanobiotix SA also collaborates with leading academic institutions and pharmaceutical companies to further advance its research and development efforts.

Nanobiotix의 P/E 비율은 -2.69입니다.

Nanobiotix의 P/S 비율은 6.33입니다.

Nanobiotix에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Nanobiotix 매출은 20.49 백만 EUR입니다.

예상되는 Nanobiotix 이익은 -48.21 백만 EUR입니다.

Nanobiotix SA is a French company specializing in the development of nanomedicine for cancer treatment. It has its headquarters in Paris and also has offices in the United States and Asia. The company's flagship product is NBTXR3, a nanoparticle technology platform that enables targeted delivery of radiation and other drugs to tumors, increasing treatment effectiveness. Nanobiotix also conducts research programs to discover and develop new nanoparticle candidates for cancer treatment and collaborates with other pharmaceutical companies through partnerships. Overall, Nanobiotix aims to establish NBTXR3 for use in multiple indications and continues to explore and develop new technologies for fighting cancer.

Nanobiotix은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Nanobiotix의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Nanobiotix의 ISIN은 FR0011341205입니다.

Nanobiotix의 WKN은 A1J7EB입니다.

Nanobiotix의 티커는 NANO.PA입니다.

지난 12개월 동안 Nanobiotix은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Nanobiotix은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Nanobiotix의 현재 배당 수익률은 입니다.

Nanobiotix은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Nanobiotix은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Nanobiotix은 '건강' 섹터에 속합니다.

Nanobiotix의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Nanobiotix는 0 EUR를 배당금으로 지급했습니다.

Nanobiotix의 배당금은 EUR에 지급됩니다.